Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Levonketoconazole withdrawal study in endogenous Cushing syndrome after open-label treatment
MOH_2017-12-06_002015Phase 3Not yet recruiting
- Sponsor
- Strongbridge Biopharma
- Start
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of levoketoconazole in endogenous Cushing's syndrome (3 arms), sponsored by Strongbridge Biopharma. Planned start Nov 2017; status: not yet recruiting.
02
Drugs
levoketoconazole
03
Conditions
endogenous Cushing's syndrome
Beyond the preview
Go deeper on MOH_2017-12-06_002015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-12-06_002015.